OC
MRNA icon

Oppenheimer & Co’s Moderna MRNA Stock Holding History

Oppenheimer & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Sell
8,817
-3,150
-26% -$163K 0.01% 1161
2026
Q1 		$608K Buy
11,967
+5,130
+75% +$239K 0.01% 1100
2025
Q4 		$202K Buy
+6,837
New +$186K ﹤0.01% 1432
2025
Q3 		– Sell
-8,888
Closed -$245K – 1709
2025
Q2 		$245K Sell
8,888
-1,331
-13% -$35.1K ﹤0.01% 1423
2025
Q1 		$290K Buy
10,219
+255
+3% +$9.05K ﹤0.01% 1300
2024
Q4 		$414K Sell
9,964
-27,823
-74% -$1.33M 0.01% 1137
2024
Q3 		$2.53M Sell
37,787
-5,144
-12% -$472K 0.04% 476
2024
Q2 		$5.1M Buy
42,931
+2,626
+7% +$332K 0.08% 270
2024
Q1 		$4.29M Buy
40,305
+8,214
+26% +$828K 0.07% 307
2023
Q4 		$3.19M Sell
32,091
-12,611
-28% -$1.06M 0.06% 369
2023
Q3 		$4.62M Buy
44,702
+769
+2% +$85.8K 0.1% 245
2023
Q2 		$5.34M Sell
43,933
-2,766
-6% -$369K 0.11% 219
2023
Q1 		$7.17M Buy
46,699
+1,606
+4% +$265K 0.15% 157
2022
Q4 		$8.1M Sell
45,093
-3,989
-8% -$652K 0.18% 129
2022
Q3 		$5.8M Sell
49,082
-3,663
-7% -$556K 0.14% 181
2022
Q2 		$7.53M Sell
52,745
-14,369
-21% -$2.05M 0.16% 138
2022
Q1 		$11.6M Buy
67,114
+7,316
+12% +$1.23M 0.21% 94
2021
Q4 		$15.2M Sell
59,798
-8,968
-13% -$2.62M 0.27% 73
2021
Q3 		$26.5M Sell
68,766
-21,558
-24% -$7.95M 0.5% 28
2021
Q2 		$21.2M Sell
90,324
-8,470
-9% -$1.51M 0.38% 47
2021
Q1 		$12.9M Buy
98,794
+25,539
+35% +$3.7M 0.26% 82
2020
Q4 		$7.65M Sell
73,255
-93
-0.1% -$9.41K 0.16% 135
2020
Q3 		$5.19M Buy
73,348
+4,298
+6% +$300K 0.13% 171
2020
Q2 		$4.43M Buy
69,050
+29,558
+75% +$1.62M 0.11% 198
2020
Q1 		$1.18M Buy
+39,492
New +$909K 0.04% 468

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Oppenheimer & Co's MRNA Position: Q2 2026 in Review

Oppenheimer & Co reduced its Moderna (MRNA) stake by 26% in Q2 2026, selling an estimated $163K and leaving 8,817 shares worth $617K. The position accounts for 0.01% of the portfolio, ranked #1161.

Oppenheimer & Co first reported a position in MRNA in Q1 2020 and has held it in 25 quarters since. The position peaked at $26.5M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Oppenheimer & Co held 8,817 shares of Moderna worth $617K as of Q2 2026.
  • Oppenheimer & Co sold 3,150 Moderna shares in Q2 2026, an estimated $163K.
  • Moderna made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1161 holding.
  • Oppenheimer & Co first reported a position in Moderna in Q1 2020 and has held it in 25 quarters since.
  • Oppenheimer & Co's Moderna position peaked at $26.5M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.